6160.HK - BeiGene, Ltd.
BeiGene, Ltd.
94 Solaris Avenue
Camana Bay
Grand Cayman KY1-1108
Cayman Islands
https://www.beigene.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 9,400
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. John V. Oyler | Co-Founder, Exec. Chairman & CEO | 2.05M | N/A | 1968 |
| Dr. Xiaobin Wu Ph.D. | Pres, COO & GM of China | 1.69M | N/A | 1962 |
| Dr. Xiaodong Wang Ph.D. | Co- Chairman of Scientific Advisory Board & Non-Exec. Director Co-Founder | 250k | N/A | 1963 |
| Ms. Julia Wang | CFO & Principal Accounting Officer | 964.2k | N/A | 1972 |
| Mr. Wang Lai | Global Head of R&D | 996.92k | 9.13M | 1977 |
| Mr. Kevin C. Mannix | Sr. VP of Investor Relations. | N/A | N/A | N/A |
| Mr. Chan Lee | Gen. Counsel & Sr. VP | N/A | N/A | N/A |
| Dr. Yan Qi | Sr. VP & Head of Public Affairs - Greater China | N/A | N/A | N/A |
| Mr. Jason W. Radford | Sr. VP of Strategy & Corp. Devel. | N/A | N/A | 1982 |
| Dr. Mark Lanasa | Sr. VP & Chief Medical Officer for Solid Tumors | N/A | N/A | N/A |
Description
BeiGene, Ltd., a biotechnology company, develops and commercializes oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; Tislelizumab to treat various solid tumor and blood cancers; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumor malignancies; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company is also developing Zanubrutinib to treat B-cell malignancies; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Ociperlimab for treating solid tumors, cervical cancer, and NSCLC; Surzebiclimab, BGB-A445, BGB-15025, Lifirafenib, BGB-24714, and BGB-B167 to treat solid tumors; BGB-10188 for treating solid tumors, B-cell lymphoid malignancies, and B-cell malignancies; BGB-11417 to treat R/R chronic lymphocytic leukemia/ small lymphocytic lymphoma, R/R mantle cell lymphoma, Mature B-cell malignancies, Myeloid malignancies, and R/R multiple myeloma; BGB-16673 for B-cell malignancies; and BGB-23339 for Inflammation and immunology. The company has collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, Bristol Myers Squibb company, Shandong Luye Pharmaceutical Co., Ltd., Nanjing Leads Biolabs, Inc., EUSA Pharma, Assembly Biosciences, Inc., Bio-Thera Solutions, Ltd., and Enlivex Therapeutics Ltd. BeiGene, Ltd. was incorporated in 2010 and is based in Grand Cayman, the Cayman Islands.
Corporate Governance
BeiGene, Ltd.’s ISS Governance QualityScore as of June 1, 2023 is 6. The pillar scores are Audit: 8; Board: 4; Shareholder Rights: 6; Compensation: 8.
